

Cancer Association of South Africa (CANSA)




Fact Sheet on Adult Acute Myeloid Leukaemia (AML)

Introduction

The word *leukaemia* literally means 'white blood' and is used to describe a variety of cancers that begin in the blood-forming cells (lymphocytes) of the bone marrow.

[Picture Credit: Acute Myeloid Leukaemia Bone Marrow Aspirate]



Adult Acute Myeloid Leukaemia (AML)

It is said that adult Acute Myeloid Leukaemia (AML) is the most common type of acute leukaemia diagnosed in adults. This could, however, not be confirmed for South Africa as the National Cancer Registry does not differentiate between the different cancers – all leukaemias are listed in combined fashion.

Incidence of Adult Acute Myeloid Leukaemia (AML)

In providing the incidence figures of Leukaemia in South Africa, the outdated National Cancer Registry (2017) does not make provision for the reporting of the different types of Leukaemia – it also does not differentiate between acute and chronic Leukaemia - neither does it provide for different statistics for cases of adult and childhood Leukaemia - except in the 'Frequency of Histologically Diagnosed Cancer in South Africa' Section of the Registry .

According to the National Cancer Registry (2017) the following number of Leukaemia cases was histologically diagnosed in South Africa during 2017:

Group - Males 2017	Actual No of Cases	Estimated Lifetime Risk	Percentage of All Cancers
All males	338	1:634	0,65%
Asian males	7	1:1 000	1,72%
Black males	151	1:1 357	1,12%
Coloured males	29	1:862	0,58%
White males	151	1:209	0,72%

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

January 2021

Group - Females 2017	Actual No of Cases	Estimated Lifetime Risk	Percentage of All Cancers
All females	230	1:1 289	0,55%
Asian females	8	1:1 010	0,62%
Black females	106	1:2 410	0,56%
Coloured females	25	1:1 074	0,53%
White females	91	1:455	0,52%

The frequency of histologically diagnosed cases of Leukaemia in South Africa for 2017 was as follows (National Cancer Registry, 2017):

Group - Males 2017	0 – 19 Years	20 – 29 Years	30 – 39 Years	40 – 49 Years	50 – 59 Years	60 – 69 Years	70 – 79 Years	80+ Years
All males	82	21	29	33	54	61	42	16
Asian males	0	0	3	1	1	1	1	0
Black males	66	110	19	16	16	19	4	1
Coloured males	7	2	1	4	6	3	5	1
White males	9	9	6	12	31	38	3	14

Group - Females 2017	0 – 19 Years	20 – 29 Years	30 – 39 Years	40 – 49 Years	50 – 59 Years	60 – 69 Years	70 – 79 Years	80+ Years
All females	40	17	20	28	31	39	37	18
Asian females	1	1	0	0	2	3	1	0
Black females	32	10	12	12	15	14	2	4
Coloured females	1	3	5	5	4	6	5	1
White females	6	3	11	11	10	16	29	13

N.B. In the event that the totals in any of the above tables do not tally, this may be the result of uncertainties as to the age, race or sex of the individual. The totals for 'all males' and 'all females', however, always reflect the correct totals.

Vakiti, A. & Mewawalla, P. 2020,

“Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases. It is characterized by clonal expansion of immature “blast cells” in the peripheral blood and bone marrow resulting in ineffective erythropoiesis and bone marrow failure. With recent advancements in the management guidelines, the cure rates have increased up to 15% in patients older than 60 years and about 40% in patients below 60 years of age. Despite advancements in therapeutic regimens, the prognosis remains very poor in the elderly population.”

Causes of Adult Acute Myeloid Leukaemia (AML)

In most cases the causes of AML remain largely unknown but it is thought to result from damage to one or more of the genes that normally control blood cell development. Research is going on all the time into finding possible causes. Certain factors have been identified that may put some people at an increased risk.

A study was conducted in the United States of America (Tsai, *et al.*, 2014) into occupations and adult acute myeloid leukaemia (AML) – no corresponding research or information could be found for South Africa.

Individuals working in the following sectors had an increased risk of AML:

- Agriculture, forestry, fishing and hunting
- Non-durable goods manufacturing

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

January 2021

- Healthcare support occupations
- Building and grounds cleaning and maintenance occupations
- Farming, fishing and forestry occupations
- Construction and extraction occupations
- Installation, maintenance and repair occupations
- Production occupations

Risk Factors for Adult Acute Myeloid Leukaemia (AML)

Anything that increases one's risk of getting a disease is called a risk factor. Having a risk factor does not mean that one will get cancer; not having risk factors does not mean that one will not get cancer.

Possible risk factors for AML include the following:

- Being male.
- Smoking, especially after age 60.
- Having had treatment with chemotherapy or radiation therapy in the past.
- Having had treatment for childhood acute lymphoblastic leukaemia (ALL) in the past.
- Being exposed to radiation from an atomic bomb or to the chemical benzene.
- Having a history of a blood disorder such as myelodysplastic syndrome.

Signs and Symptoms of Adult Acute Myeloid Leukaemia (AML)

Typically AML comes on suddenly, within days or weeks. Less often, a patient has been ill for a few months or may have a prior history of Myelodysplastic Syndrome.

AML makes people sick primarily by interfering with normal bone marrow function. The leukaemia cells replace and crowd out the normal cells of the bone marrow, thereby causing low blood cell counts. This insufficient number of red blood cells results in a condition called anaemia, which causes a person to be tired and pale. Lack of platelets can make one more susceptible to bleeding and bruising, especially in the skin, nose and gums. Lowered levels of normal white blood cells increase the risk of infection.

Although infections can be of any type, typical symptoms include:

- Fever
- Lethargy and fatigue
- Pale skin
- Easy bruising
- Swollen lymph nodes
- Swollen gums
- Unusual bleeding, such as frequent nosebleeds and bleeding from the gums
- Bone pain
- Abdominal discomfort due to swollen liver or spleen
- Infections of the bloodstream, called sepsis

Mądry, K., Lis, K., Biecek, P., Młynarczyk, M., Rytel, J., Górka, M., Kacprzyk, P., Dutka, M., Rodzaj, M., Bołkun, Ł., Krochmalczyk, D., Łątka, E., Drozd-Sokołowska, J., Waszczuk-Gajda, A., Knopińska-Postuszny, W., Kopińska, A., Subocz, E., Masternak, A., Guzicka-Kazimierczak, R., Gil, L., Machowicz, R., Biliński, J., Giebel, S., Czerw, T. & Dwilewicz-Trojaczek, J. 2019.

BACKGROUND: Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) patients, including those treated with azacitidine, are at increased risk for serious infections. The aim of our study was to identify patients with higher infectious risk at the beginning of azacitidine treatment.

PATIENTS AND METHODS: We performed a retrospective evaluation of 298 MDS/CMML/AML patients and included in the analysis 232 patients who completed the first 3 cycles of azacitidine therapy or developed Grade III/IV infection before completing the third cycle.

RESULTS: Overall, 143 patients (62%) experienced serious infection, and in 94 patients (41%) infection occurred within the first 3 cycles. The following variables were found to have the most significant effect on the infectious risk in multivariate analysis: red blood cell transfusion dependency (odds ratio [OR], 2.38; 97.5% confidence interval [CI], 1.21-4.79), neutropenia $<0.8 \times 10^9/L$ (OR, 3.03; 97.5% CI, 1.66-5.55), platelet count $<50 \times 10^9/L$ (OR, 2.63; 97.5% CI, 1.42-4.76), albumin level <35 g/dL (OR, 2.04; 97.5% CI, 1.01-4.16), and Eastern Cooperative Oncology Group performance status ≥ 2 (OR, 2.19; 97.5% CI, 1.40-3.54). Each of these variables is assigned 1 point, and the combined score represents the proposed Azacitidine Infection Risk Model. The infection rate in the first 3 cycles of therapy in lower-risk (0-2 score) and higher-risk (3-5 score) patients was 25% and 73%, respectively. The overall survival was significantly reduced in higher-risk patients compared with the lower-risk cohort (8 vs. 29 months).

CONCLUSION: We selected a subset with high early risk for serious infection and worse clinical outcome among patients treated with azacitidine.

Diagnosis of Adult Acute Myeloid Leukaemia (AML)

Tests that examine the blood and bone marrow are usually used to detect (find) and diagnose adult AML.

The following tests and procedures may be used:

- Physical examination and history: An examination of the body to check general signs of health, including checking for signs of disease, such as lumps or anything else that seems unusual. A history of the patient's health habits and past illnesses and treatments is also usually taken
- Complete Blood Count (CBC): A procedure in which a sample of blood is drawn and checked for the following:
 - The number of red blood cells, white blood cells, and platelets
 - The amount of haemoglobin (the protein that carries oxygen) in the red blood cells
 - The portion of the sample made up of red blood cells
- Bone marrow aspiration and biopsy
- A laboratory test in which the cells in a sample of blood or bone marrow are viewed to look for certain changes in the chromosomes
- Immunophenotyping: A process used to identify cells, based on the types of antigens or markers on the surface of the cell

- Reverse transcription–polymerase chain reaction test (RT–PCR): A laboratory test in which cells in a sample of tissue are studied using chemicals to look for certain changes in the structure or function of genes

Narayanan, D. & Weinberg, O.K. 2020.

“Acute myeloid leukemia (AML) is a neoplasm of immature myeloid cells and is associated with a wide variety of clinical presentations, morphological features, immunophenotypes, and genetic findings. Recent advances in identification of cytogenetic abnormalities and mutations have provided novel insights into the pathogenesis of AML. Based on the above-mentioned parameters, the World Health Organization (WHO) classified AML into 25 subtypes, including 2 provisional entities, which differ in prognosis and treatment. In addition, certain mutations are associated with germline predisposition and increase the risk of inherited AML, which warrants family screening. Therefore, precise diagnosis and classification of AML are the most important steps in patient management. Both these steps require incorporation of history, clinical presentation, and laboratory results with studies performed by a pathologist. Pathologist-initiated studies include morphologic evaluation on the bone marrow aspirate and/or core biopsy, immunophenotyping by flow cytometry and/or immunohistochemistry, cytogenetic analysis by karyotyping and/or fluorescence in situ hybridization, and molecular testing using gene panels and/or next-generation sequencing. A similar approach is employed during follow-up of patients after beginning treatment. Here, we describe in detail the various aspects of the workup, including purpose, limitations, and practice guidelines for the different studies. The process of choosing appropriate materials for the different studies is also addressed. We also provide an algorithm for the workup and risk stratification of AML based on guidelines recommended by the WHO, College of American Pathologists, National Comprehensive Cancer Network, American Society of Clinical Oncology, European Society of Medical Oncology, and the European LeukemiaNet.”

Treatment of Adult Acute Myeloid Leukaemia (AML)

The usual treatment of AML is usually divided into two phases: induction of remission and post-remission therapy.

Induction therapy - the initial phase of treatment is referred to as remission induction or ‘induction’ therapy. Induction therapy is given with the goal of decreasing the number of leukaemia cells to an undetectable level and restoring the production of normal blood cells.

Complete remission — the first goal of AML treatment is to achieve a complete remission. Complete remission means that there is no visible evidence of leukaemia cells in the blood or bone marrow and the bone marrow is functioning normally. A bone marrow biopsy and blood testing are done to determine when/if this occurs.

Post-remission therapy - is given with the intention of killing leukaemia cells that can remain in the bone marrow or blood, but are undetectable under the microscope.

Additional chemotherapy — chemotherapy given after remission is called remission consolidation or post-remission chemotherapy

DiNardo, C.D., Jonas, B.A., Pullarkat, V., Thirman, M.J., Garcia, J.S., Wei, A.H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., Koller, E., Havelange, V., Leber, B., Esteve, J., Wang, J., Pejsa, V., Hájek, R., Porkka, K., Illés, Á., Lavie, D., Lemoli, R.M., Yamamoto, K., Yoon, S.S., Jang, J.H., Yeh, S.P., Turgut, M., Hong, W.J., Zhou, Y., Potluri, J., Pratz, K.W. 2020.

Background: Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.

Methods: We randomly assigned previously untreated patients with confirmed AML who were ineligible for standard induction therapy because of coexisting conditions, because they were 75 years of age or older, or both to azacitidine plus either venetoclax or placebo. All patients received a standard dose of azacitidine (75 mg per square meter of body-surface area subcutaneously or intravenously on days 1 through 7 every 28-day cycle); venetoclax (target dose, 400 mg) or matching placebo was administered orally, once daily, in 28-day cycles. The primary end point was overall survival.

Results: The intention-to-treat population included 431 patients (286 in the azacitidine-venetoclax group and 145 in the azacitidine-placebo [control] group). The median age was 76 years in both groups (range, 49 to 91). At a median follow-up of 20.5 months, the median overall survival was 14.7 months in the azacitidine-venetoclax group and 9.6 months in the control group (hazard ratio for death, 0.66; 95% confidence interval, 0.52 to 0.85; $P < 0.001$). The incidence of complete remission was higher with azacitidine-venetoclax than with the control regimen (36.7% vs. 17.9%; $P < 0.001$), as was the composite complete remission (complete remission or complete remission with incomplete hematologic recovery) (66.4% vs. 28.3%; $P < 0.001$). Key adverse events included nausea of any grade (in 44% of the patients in the azacitidine-venetoclax group and 35% of those in the control group) and grade 3 or higher thrombocytopenia (in 45% and 38%, respectively), neutropenia (in 42% and 28%), and febrile neutropenia (in 42% and 19%). Infections of any grade occurred in 85% of the patients in the azacitidine-venetoclax group and 67% of those in the control group, and serious adverse events occurred in 83% and 73%, respectively.

Conclusions: In previously untreated patients who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received azacitidine alone. The incidence of febrile neutropenia was higher in the venetoclax-azacitidine group than in the control group. (Funded by AbbVie and Genentech; [VIALE-A ClinicalTrials.gov number, NCT02993523](https://clinicaltrials.gov/ct2/show/study/NCT02993523).)

Ghosh, A., Barba, P. & Perales, M-A. 2020.

“Immunotherapy is distinct from traditional chemotherapy in that it acts on immune cells rather than cancer cells themselves. Monoclonal antibodies targeting immune checkpoints on T cells - CTLA-4 and PD-1 - and PD-L1 on the cells of immune microenvironment are now approved for clinical use in several solid tumors and hematological malignancies. This article provides a general overview of the use of checkpoint inhibitors in hematologic malignancies with a special focus in acute myeloid leukemia.”

Stem cell transplantation — stem cell transplantation, also called bone marrow transplantation or haematopoietic stem cell transplantation

Flores-Jiménez, J.A., Pimentel-Morales, M.A., González-Ramella, O., Vega-Cortés, D. & Zambrano-Velarde, M.Á. 2019.

“Acute myelogenous leukemia (AML) represents ~33% of those in adolescents and young adults. Hematopoietic cell transplantation in its various practices has been used as a treatment for acute myeloid leukemia, especially in refractory or relapsing patients. In this study, we describe two young adults with AML who were treated at our hospital. One was refractory to conventional treatment and the other case was relapsed after a first complete remission. They achieved complete remission with new combined treatment (venetoclax + cytarabine) consolidating them with hematopoietic stem cell transplantation.”

Allogeneic transplantation - uses stem cells from a healthy donor, ideally a sibling with a similar genetic makeup (called an HLA-matched related donor; MRD).

Loke, J., Malladi, R., Moss, P. & Craddock, C. 2020.

“Acute myeloid leukaemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The accumulated experience of allografting in AML over the last four decades has provided critical insights into both the contribution of the conditioning regimen and the graft-versus-leukaemia effect to the curative potential of the most common form of immunotherapy utilised in standard clinical practice. Coupled with advances in donor availability and transplant technologies, this has resulted in allo-SCT becoming an important treatment modality for the majority of adults with high-risk AML. At the same time, advances in genomic classification, coupled with progress in the accurate quantification of measurable residual disease, have increased the precision with which allo-mandatory patients can be identified, whilst simultaneously permitting accurate identification of those patients who can be spared the toxicity of an allograft. Despite this progress, disease recurrence still remains a major cause of transplant failure and AML has served as a paradigm for the development of strategies to reduce the risk of relapse - notably the novel concept of post-transplant maintenance, utilising pharmacological or cellular therapies.”

Bonifazi, F., Solano, C., Wolschke, C., Sessa, M., Patriarca, F., Zallio, F., Nagler, A., Selleri, C., Risitano, A.M., Messina, G., Bethge, W., Herrera, P., Sureda, A., Carella, A.M., Cimminiello, M., Guidi, S., Finke, J., Sorasio, R., Ferra, C., Sierra, J., Russo, D., Benedetti, E., Milone, G., Benedetti, F., Heinzlmann, M., Pastore, D., Jurado, M., Terruzzi, E., Narni, F., Völp, A., Ayuk, F., Ruutu, T. & Kröger, N. 2019.

BACKGROUND: We previously showed that human anti-T-lymphocyte globulin (ATLG) plus ciclosporin and methotrexate given to patients with acute leukaemia in remission, having allogeneic haemopoietic stem-cell transplantation with peripheral blood stem cells from an HLA-identical sibling donor after myeloablative conditioning, significantly reduced 2-year chronic graft-versus-host disease (cGVHD) incidence and severity, without increasing disease relapse and infections, and improves cGVHD-free and relapse-free survival (cGRFS). The aim of an extended follow-up study was the assessment of long-term outcomes, which are, in this context, scarcely reported in the literature. We report unpublished data on quality of life (QoL) from the original study and the results of a follow-up extension.

METHODS: In the original open-label study, patients with acute myeloid and lymphoblastic leukaemia in first or subsequent remission, having sibling HLA-identical allogeneic peripheral blood stem-cell transplantation, were randomly assigned (1:1) to receive ATLG plus standard GVHD prophylaxis with ciclosporin and short-term methotrexate (ATLG group) or standard GVHD prophylaxis without ATLG (non-ATLG group). Conditioning regimens were cyclophosphamide 120 mg/kg with either total body irradiation (12 Gy) or busulfan (12·8 mg/kg intravenously or 16 mg/kg orally), with or without etoposide (30-60 mg/kg). Randomisation was stratified according to centre and disease risk. The primary endpoint was cumulative incidence of cGVHD at 2 years. The

primary and secondary endpoints, excluding QoL, have been published. QoL, assessed using European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-HDC29 questionnaires, was an unpublished secondary endpoint, which we now report here. A follow-up extension was then done, with the primary endpoint cumulative incidence of cGVHD. Enrolment has been completed for both studies. The original trial (number, [NCT00678275](#)) and follow-up extension (number, [NCT03042676](#)) are registered at ClinicalTrials.gov.

FINDINGS: In the original study, from Dec 14, 2006, to Feb 2, 2012, 161 patients were enrolled and 155 were randomly assigned to either the ATLG group (n=83) or to the non-ATLG group (n=72). In the follow-up study, which started on Feb 7, 2017, and was completed on June 30, 2017, 61 patients were included in the ATLG group and 53 were included in the non-ATLG group. Global health status showed a more favourable time course in the ATLG group compared with the non-ATLG group (p=0.02; treatment by visit interaction). ATLG was descriptively superior to non-ATLG at 24 months for physical function (points estimate -14.8 [95% CI -26.4 to -3.1]; p=0.014) and social function (-19.1 [-38.0 to -0.2]; p=0.047), gastrointestinal side-effects (8.8 [2.5-15.1]; p=0.008) and effect on family (13.5 [1.2-25.8]; p=0.032). Extended follow-up (median 5.9 years [IQR 1.7-7.9]) confirmed a lower 5-year cGVHD incidence (30.0% [95% CI 21.4-41.9] vs 69.1% [59.1-80.1]; analysis for entire follow-up, p<0.001), no increase in relapses (35.4% [26.4-47.5] vs 22.5% [14.6-34.7]; p=0.09), improved cGRFS (34.3% [24.2-44.5] vs 13.9% [7.1-22.9]; p=0.005), and fewer patients still in immunosuppression (9.6% vs 28.3%; p=0.017) in the ATLG group compared with the non-ATLG group. 5-year overall survival, relapse-free survival, and non-relapse mortality did not differ significantly between groups.

INTERPRETATION: The addition of ATLG to standard GVHD prophylaxis improves the probability of surviving without disease relapse and cGVHD after myeloablative peripheral blood stem-cell transplantation from an HLA-identical sibling donor for patients with acute leukaemia in remission. Further additional benefits are better QoL and shorter immunosuppressive treatment compared with standard GVHD prophylaxis without ATLG. Therefore, in this setting, ATLG plus standard GVHD prophylaxis should be preferred over the standard GVHD prophylaxis alone.

Autologous transplant – the patient’s own normal stem cells are collected while in complete remission.

Hatsumi, N., Miyawaki, S., Yamauchi, T., Takeshita, A., Komatsu, N., Usui, N., Arai, Y., Ishida, F., Morii, T., Kano, Y., Ogura, M., Machida, S., Nishii, K., Honda, S., Ohnishi, K., Naoe, T. & Japan Adult Leukemia Study Group (JALSG). 2019.

“Given the poor prognosis of patients with relapsed/refractory acute myeloid leukemia (AML), better therapy is needed. Fludarabine enhances the efficacy of Ara-C (cytarabine) by increasing intracellular Ara-C-triphosphate. The FLAG (fludarabine, high-dose Ara-C, supported with granulocyte colony-stimulating factor) regimen has been tested for use in AML patients by other investigators. In the phase II study reported here, we evaluated the efficacy and toxicity of FLAGM therapy (FLAG with mitoxantrone), further intensified by adding mitoxantrone, based on the results of a phase I study by our group. The major endpoints were complete remission (CR) rate and early death. From June 2004 to February 2008, 41 patients (median age 52 years; range 18-64 years) were enrolled. Thirty (73% 95% CI 58-84%) patients achieved CR, which met the primary endpoint; there was a single case of early death from pneumonia. Two-year overall survival was 39.4% (95% CI 25.2-55.6%). Of those who achieved CR, 27 underwent allogeneic stem cell transplantation (SCT), and 12 SCT recipients showed long-term survival. Grade 3/4 non-hematological adverse events included infection (59%), nausea/vomiting (15%), diarrhea (7%), and elevated liver enzymes (7%). In

conclusion, FLAGM is an effective and safe salvage therapy for patients with relapsed/refractory AML, and facilitated SCT for a large proportion of patients.”

Kanakasetty, G.B., R. C., K. C. L., Dasappa, L., Jacob, L.A., M. C. S.B., K. N. L., Haleshappa, R.A., L. K. R., Saldanha, S.C., Deepak, K., Rajesh, P. & Asati, V. 2019.

“Elderly patients with acute myeloid leukemia have a poor prognosis. Data from developing countries is sparse in the literature. In this retrospective study, 402 patients aged ≥ 60 years, diagnosed between Jan 2013 and Dec 2017, were analyzed for treatment patterns and survival. Median age of the whole cohort was 68 years (range 61-84). A total of 213 patients (53.3%) refused care; 188 patients (46.7%) received either BSC, LDAC, or HMA. Survival (in months) was 3.9, 6.4, and 1.2 with LDAC, HMA, and BSC, respectively. One-year survival was 17.2% and 6% with HMA and LDAC, respectively ($P = 0.02$). Overall response rate (ORR) did not differ between HMA and LDAC group ($p = 0.12$). HMA cohort had higher complete responses (20.6% vs 7.4%, $p = 0.02$), stable disease (32.7% vs 13.5%, $p = 0.02$), and transfusion independence (TI) (46.5% vs 22.2%, $p = 0.01$). Survival did not differ between the groups if the patients achieved ORR (12.3 vs 9.8 $p = 0.2$) or TI (11.6 vs 6.4 $p = 0.2$). Stable disease with HMA led to longer survival (8.1 vs 5.3 $p = 0.01$). HMAs were more effective than LDAC irrespective of cytogenetic risk category and blasts, of note HMAs improved survival of poor risk patients (5.6 vs 2.9 $p = 0.004$). HMA treatment (HR = 0.48; 95% 0.29-0.79, $p = 0.004$) and transfusion independence (HR = 0.2; 95% 0.1-0.3, $p = 0.0001$) predicted survival in multivariate analysis. Neutropenia and febrile neutropenia were frequent in HMA. Thrombocytopenia was the common adverse event with LDAC. Novel and cost-effective drugs are essential to improve the prognosis of these patients.”

Chaer, F.El. & Ballen, K.K. 2020.

“Since Jehovah's Witness (JW) patients diagnosed with leukaemia refuse blood transfusions, they are often denied intensive chemotherapy for fear they could not survive myeloablation without blood transfusion support. Treatment of JW patients with acute leukaemia is challenging and carries a higher morbidity and mortality; however, the refusal of blood products should not be an absolute contraindication to offer multiple treatment modalities including haematopoietic stem cell transplantation. In this review we discuss their optimal management and describe alternative modalities to blood transfusions to provide sufficient oxygenation and prevent bleeding.”

About Clinical Trials

Clinical trials are research studies that involve people. They are conducted under controlled conditions. Only about 10% of all drugs started in human clinical trials become an approved drug.

Clinical trials include:

- Trials to test effectiveness of new treatments
- Trials to test new ways of using current treatments
- Tests new interventions that may lower the risk of developing certain types of cancers
- Tests to find new ways of screening for cancer

The [South African National Clinical Trials Register](#) provides the public with updated information on clinical trials on human participants being conducted in South Africa. The Register provides information on the purpose of the clinical trial; who can participate, where the trial is located, and contact details.

For additional information, please visit: www.sanctr.gov.za/

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

January 2021

Medical Disclaimer

This Fact Sheet is intended to provide general information only and, as such, should not be considered as a substitute for advice, medically or otherwise, covering any specific situation. Users should seek appropriate advice before taking or refraining from taking any action in reliance on any information contained in this Fact Sheet. So far as permissible by law, the Cancer Association of South Africa (CANSA) does not accept any liability to any person (or his/her dependants/estate/heirs) relating to the use of any information contained in this Fact Sheet.

Whilst CANSA has taken every precaution in compiling this Fact Sheet, neither it, nor any contributor(s) to this Fact Sheet can be held responsible for any action (or the lack thereof) taken by any person or organisation wherever they shall be based, as a result, direct or otherwise, of information contained in, or accessed through, this Fact Sheet.



References and Sources Consulted or Utilised

Acute Myeloid Leukaemia

<https://www.travcure.com/low-cost-acute-myeloid-leukemia-treatment-in-india/>

Bonifazi, F., Solano, C., Wolschke, C., Sessa, M., Patriarca, F., Zallio, F., Nagler, A., Sella, C., Risitano, A.M., Messina, G., Bethge, W., Herrera, P., Sureda, A., Carella, A.M., Cimminiello, M., Guidi, S., Finke, J., Sorasio, R., Ferra, C., Sierra, J., Russo, D., Benedetti, E., Milone, G., Benedetti, F., Heinzlmann, M., Pastore, D., Jurado, M., Terruzzi, E., Narni, F., Völp, A., Ayuk, F., Ruutu, T. & Kröger, N. 2019. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. *Lancet Haematol.* 2019 Feb;6(2):e89-e99. doi: 10.1016/S2352-3026(18)30214-X. Erratum in: *Lancet Haematol.* 2019. March: 6(3):e121. PMID: 30709437.

Chaer, F.El. & Ballen, K.K. 2020. Treatment of acute leukaemia in adult Jehovah's Witnesses. *Br J Haematol.* 2020 Sep;190(5):696-707.

DiNardo, C.D., Jonas, B.A., Pullarkat, V., Thirman, M.J., Garcia, J.S., Wei, A.H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., Koller, E., Havelange, V., Leber, B., Esteve, J., Wang, J., Pejsa, V., Hájek, R., Porkka, K., Illés, Á., Lavie, D., Lemoli, R.M., Yamamoto, K., Yoon, S.S., Jang, J.H., Yeh, S.P., Turgut, M., Hong, W.J., Zhou, Y., Potluri, J., Pratz, K.W. 2020. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *N Engl J Med.* 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.

Flores-Jiménez, J.A., Pimentel-Morales, M.A., González-Ramella, O., Vega-Cortés, D. & Zambrano-Velarde, M.Á. 2019. Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases. *J Adolesc Young Adult Oncol.* 2019 Mar 5. doi: 10.1089/jayao.2018.0137. [Epub ahead of print]. PMID: 30835153.

Geiger, T.L. & Rubnitz, J.E. 2015. New approaches for the immunotherapy of acute myeloid leukemia. *Discov Med.* 2015. Apr. 19(105):275-84.

Ghosh, A., Barba, P. & Perales, M-A. 2020. Checkpoint inhibitors in AML: are we there yet?. *Br J Haematol.* 2020 Jan;188(1):159-167.

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

January 2021

Hatsumi, N., Miyawaki, S., Yamauchi, T., Takeshita, A., Komatsu, N., Usui, N., Arai, Y., Ishida, F., Morii, T., Kano, Y., Ogura, M., Machida, S., Nishii, K., Honda, S., Ohnishi, K., Naoe, T. & Japan Adult Leukemia Study Group (JALSG). 2019. Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia. *Int J Hematol*. 2019 Feb 6. doi: 10.1007/s12185-019-02606-0. [Epub ahead of print]. PMID: 30725360.

Kanakasetty, G.B., R, C., K. C. L., Dasappa, L., Jacob, L.A., M. C. S.B., K. N. L., Haleshappa, R.A., L. K. R., Saldanha, S.C., Deepak, K., Rajesh, P. & Asati, V. 2019. Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India. *Ann Hematol*. 2019 Apr;98(4):881-888. doi: 10.1007/s00277-019-03600-6. Epub 2019 Jan 29. PMID: 30697642.

Lagunas-Rangel, F.A., Chávez-Valencia, V., Gómez-Guijosa, M.Á. & Cortes-Penagos, C. 2017. Acute myeloid leukemia: genetic alterations and their clinical prognosis. *Int J Hematol Oncol Stem Cell Res*. 2017 Oct 1;11(4):328-339. Review. PMID: 29340131.

Leukaemia and Lymphoma Research

<https://leukaemialymphomaresearch.org.uk/information/leukaemia/acute-myeloid-leukaemia-aml>

<https://leukaemialymphomaresearch.org.uk/booklet/acute-promyelocytic-leukaemia-apl>

Leukaemia Foundation

<http://www.leukaemia.org.au/blood-cancers/leukaemias/acute-myeloid-leukaemia-aml>

National Cancer Institute

<http://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials>

Loke, J., Malladi, R., Moss, P. & Craddock, C. 2020. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. *Br J Haematol*. 2020 Jan;188(1):129-146.

Mądry, K., Lis, K., Biecek, P., Młynarczyk, M., Rytel, J., Górka, M., Kacprzyk, P., Dutka, M., Rodzaj, M., Bołkun, Ł., Krochmalczyk, D., Łątka, E., Drozd-Sokołowska, J., Waszczuk-Gajda, A., Knopińska-Postuszny, W., Kopińska, A., Subocz, E., Masternak, A., Guzicka-Kazmierczak, R., Gil, L., Machowicz, R., Biliński, J., Giebel, S., Czerw, T. & Dwilewicz-Trojaczek, J. 2019. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. *Clin Lymphoma Myeloma Leuk*. 2019 Jan 23. pii: S2152-2650(18)31510-6. doi: 10.1016/j.clml.2019.01.002. [Epub ahead of print]. PMID: 30898482.

Narayanan, D. & Weinberg, O.K. 2020. How I investigate acute myeloid leukemia. *Int J Lab Hematol*. 2020 Feb;42(1):3-15.

Ogawa, H., Ikegame, K., Daimon, T., Uchida, N., Fukuda, T., Kakahana, K., Eto, T., Ozawa, Y., Kanamori, H., Hidaka, M., Iwato, Y., Ichinohe, T., Takahashi, M., Atsuta, Y. & Kanda, Y. 2018. Impact of pretransplant leukemic blasts in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation in non-CR. *Bone Marrow Transplant*. 2018 Jan 12. doi: 10.1038/s41409-017-0028-x. [Epub ahead of print] No abstract available. PMID: 29330394.

Ossenkoppele, G. & Löwenberg, B. 2015. How I treat the older patient with acute myeloid leukaemia. *Blood*. 2015 Jan 29;125(5):767-74. doi: 10.1182/blood-2014-08-551499. Epub 2014 Dec 16. PMID: 25515963. DOI: 10.1182/blood-2014-08-551499.

Tsai, R.J., Luckhaupt, S.E., Schumacher, P., Cress, R.D., Deapen, D.M. & Calvert, G.M. 2015. Acute myeloid leukemia risk by industry and occupation. *Leuk Lymphoma*. Author manuscript; available in PMC 2015 Nov 1. Published in final edited form as: *Leuk Lymphoma* 2014 Nov; 55(11): 2584-2591. Published online 2014 Mar 31. doi: 10.3109/10428194.2014.894189. PMCID: PMC4534715. NIHMSID: NIHMS710395.

Vakiti, A. & Mewawalla, P. 2020, Acute myeloid leukemia. *In*: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. 2020 Nov 21.

Visnjic, D., Dembitz, V. & Lalic, H. 2018. The role of AMPL/mTOR modulators in therapy of acute myeloid leukemia. *Curr Med Chem*. 2018 Jan 16. doi: 10.2174/0929867325666180117105522. [Epub ahead of print]. PMID: 29345570.

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

January 2021